ERBB2 and breast cancer: If untreated with appropriate HER2-directed therapy, or in cases where eBC presents with extensive local disease burden and/or lymph node involvement, HER2+ BC is associated with a poor prognosis, including high recurrence rates, an increased likelihood of brain metastases, and high mortality [6,7].